eosinophilic granulomatosis polyangiitis egpa formerly known allergic extremely rare autoimmune condition causes inflammation small mediumsized blood vessels vasculitis persons history airway allergic hypersensitivity usually manifests three stages early prodromal stage marked airway inflammation almost patients experience asthma andor allergic rhinitis second stage characterized abnormally high numbers eosinophils hypereosinophilia causes tissue damage commonly lungs digestive third stage consists vasculitis eventually lead cell death condition called eosinophilic granulomatosis polyangiitis remove eponyms vasculitides facilitate transition referred eosinophilic granulomatosis polyangiitis period time starting prior known syndrome named jacob churg lotte strauss first published syndrome using term allergic granulomatosis describe type systemic necrotizing vasculitis effective treatment egpa requires suppression immune system medication typically glucocorticoids followed agents cyclophosphamide azathioprine eosinophilic granulomatosis polyangiitis consists three stages patients develop three stages progress one stage next whereas patients may develop severe lifethreatening complications gastrointestinal involvement heart disease patients mildly affected eg skin lesions nasal egpa consequently considered highly variable condition terms presentation prodromal stage characterized allergy almost patients experience asthma andor allergic history asthma either new development worsening preexisting may require systemic corticosteroid average asthma develops three nine years signs allergic rhinitis may produce symptoms rhinorrhea nasal obstruction formation nasal polyps require surgical removal often sinusitis may also second stage characterized abnormally high level eosinophils type white blood cell blood tissues result abnormal eosinophil proliferation impaired eosinophil apoptosis increased toxicity due eosinophil metabolic normal eosinophil composition total leukocyte count elevated egpa local accumulation eosinophil involved pathogenesis asthma described allergic stage initiating maintaining immune responses symptoms hypereosinophilia depend part body affected often affects lungs digestive signs symptoms hypereosinophilia may include weight loss night sweats asthma cough abdominal pain gastrointestinal fever malaise often eosinophilic stage last months years symptoms disappear return third final stage hallmark egpa inflammation blood vessels consequent reduction blood flow various organs damage done blood vessels explained overabundance eosinophils produced flowing throughout vasculature body eosinophil production essential assisting inflammatory responses infections diseases lead tissue damage done local systemic symptoms become widespread compounded new symptoms severe complications may arise blood clots may develop within damaged arteries severe cases particularly arteries abdominal region followed infarction cell death slow many patients experience severe abdominal complaints often due peritonitis andor ulcerations perforations gastrointestinal tract occasionally due acalculous cholecystitis granulomatous serious complication vasculitic stage heart disease cause nearly onehalf deaths patients among heart diseaserelated deaths usual cause inflammation heart muscle caused high level eosinophils although deaths due inflammation arteries supply blood heart pericardial kidney complications reported less complications kidneys include glomerulonephritis prevents kidneys ability filter blood ultimately causing wastes build diagnostic markers include eosinophil granulocytes granulomas affected tissue antineutrophil cytoplasmic antibodies anca neutrophil granulocytes two pathological subsets egpa differentiated presence antineutrophil cytoplasmic antibodies anca autoantibodies mistakenly target attack specific proteins found within cytoplasm anca subtype characterized predominantly vasculitislike manifestations anca subtype commonly associated eosinophilicrelated approximately egpa cases pathogenic mechanisms fully understood finding suggests role b cells precursors ancaproducing plasma cells pathogenesis egpa american college rheumatology criteria diagnosis syndrome lists criterianeeds update classification purposes patient shall said egpa least four six criteria positive presence four six criteria yields sensitivity specificity update french vasculitis study group developed fivepoint system fivefactor score predicts risk death syndrome using clinical presentations factors none factors indicates milder case fiveyear mortality rate presence one factor indicates severe disease fiveyear mortality rate three indicate severe disease fiveyear mortality ct scan lungs peripheral parenchymal opacification pulmonary consolidation groundglass opacity middle lower zones predominant pattern interlobular septal thickening septa separating secondary pulmonary lobules due pulmonary odema secondary heart treatment eosinophilic granulomatosis polyangiitis includes glucocorticoids prednisolone immunosuppressive drugs azathioprine cyclophosphamide many cases disease put type chemical remission drug therapy disease chronic lifelongcitation needed systematic review conducted indicated patients treated highdose steroids patients fivefactor score one higher cyclophosphamide pulse therapy commenced pulses leading fewer relapses six remission maintained less toxic drug azathioprine december fda approved mepolizumab first drug therapy specifically indicated treatment eosinophilic granulomatosis patients taking mepolizumab experienced significant improvement mepolizumab monoclonal antibody targets major factor eosinophil addition mepolizumab number emerging targeted antiige monoclonal antibody omalizumab immunomodulation interferonÎ± b cell therapy lead increasingly personalized treatment regimens future egpa patients review egpa treatments conducted proposes integrating targeted biotherapies egpa management plans following failure treatment eosinophilic granulomatosis polyangiitis first described pathologists jacob churg lotte strauss mount sinai hospital new york city using term allergic granulomatosis describe reported feverhypereosinophilia symptoms cardiac failure renal damage peripheral neuropathy resulting vascular embarrassment various systems series patients necrotizing vasculitis previously diagnosed periarteritis nodosa accompanied hypereosinophilia severe churg strauss noted three features distinguished patients patients periarteritis nodosa without asthma necrotizing vasculitis tissue eosinophilia extravascular result proposed cases evident different disease entity referred allergic granulomatosis memoir patient musician ben watt everything girl fame deals experience egpa watts case unusual mainly affected gastrointestinal tract leaving lungs largely unaffected unusual presentation contributed delay proper diagnosis treatment required removal ft necrotized small intestine leaving permanently restricted umaru musa yaradua president nigeria reportedly egpa died office complications dj author charlie gillett diagnosed egpa died four years japanese ski jumper taku takeuchi bronze medal team competition disease competed sochi olympics less month released hospital new zealand reporter television presenter toni street diagnosed condition street health problems several years including removal gallbladder four months american professional basketball player willie naulls died november laguna niguel california respiratory failure due battling eight canadian standup comic candy palmater died december shortly diagnosed filipino actress kris aquino sister former philippine president benigno aquino iii revealed may diagnosed httpsenwikipediaorgwikiallergicgranulomatosis